JP2017515901A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515901A5
JP2017515901A5 JP2017511565A JP2017511565A JP2017515901A5 JP 2017515901 A5 JP2017515901 A5 JP 2017515901A5 JP 2017511565 A JP2017511565 A JP 2017511565A JP 2017511565 A JP2017511565 A JP 2017511565A JP 2017515901 A5 JP2017515901 A5 JP 2017515901A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
aryl
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511565A
Other languages
English (en)
Japanese (ja)
Other versions
JP6419313B2 (ja
JP2017515901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030014 external-priority patent/WO2015172099A1/en
Publication of JP2017515901A publication Critical patent/JP2017515901A/ja
Publication of JP2017515901A5 publication Critical patent/JP2017515901A5/ja
Application granted granted Critical
Publication of JP6419313B2 publication Critical patent/JP6419313B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511565A 2014-05-09 2015-05-08 抗ウイルスの化合物、医薬組成物およびその使用方法 Expired - Fee Related JP6419313B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US61/991,418 2014-05-09
US201562177900P 2015-03-25 2015-03-25
US62/177,900 2015-03-25
PCT/US2015/030014 WO2015172099A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017515901A JP2017515901A (ja) 2017-06-15
JP2017515901A5 true JP2017515901A5 (show.php) 2018-04-05
JP6419313B2 JP6419313B2 (ja) 2018-11-07

Family

ID=54393071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511565A Expired - Fee Related JP6419313B2 (ja) 2014-05-09 2015-05-08 抗ウイルスの化合物、医薬組成物およびその使用方法

Country Status (9)

Country Link
US (3) US9884876B2 (show.php)
EP (1) EP3139920A4 (show.php)
JP (1) JP6419313B2 (show.php)
CN (1) CN106456615B (show.php)
AU (3) AU2015255714B2 (show.php)
CA (1) CA2948178A1 (show.php)
MX (2) MX2016014642A (show.php)
TW (1) TW201623265A (show.php)
WO (1) WO2015172099A1 (show.php)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770345A (zh) 2017-04-14 2020-02-07 托尔奈公司 免疫调节多核苷酸、抗体缀合物及其使用方法
TW202021956A (zh) * 2018-08-09 2020-06-16 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
KR20210098985A (ko) * 2018-11-02 2021-08-11 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 대해 활성인 신규 우레아 6,7-디히드로-4h-티아졸로[5,4-c]피리딘
BR112021024310A2 (pt) * 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
US20220273689A1 (en) * 2019-07-09 2022-09-01 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
EP4037706A4 (en) * 2019-10-02 2023-09-13 University of Washington Compositions and methods for treatment of hepatitis b virus infection
WO2021174091A1 (en) 2020-02-28 2021-09-02 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
CN115715194A (zh) 2020-04-04 2023-02-24 辉瑞公司 治疗冠状病毒疾病2019的方法
US12358897B2 (en) 2020-04-05 2025-07-15 Pfizer Inc. Compounds and method of treating COVID-19
US12485157B2 (en) 2020-04-05 2025-12-02 Pfizer Inc. Method of treating COVID-19
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022078602A1 (en) * 2020-10-15 2022-04-21 Baden-Württemberg Stiftung Ggmbh Flavi-block: a pan-flavivirus inhibitor
WO2022180003A1 (en) * 2021-02-24 2022-09-01 F. Hoffmann-La Roche Ag Benzothiazolyl bicyclo[1.1.1]pentane derivatives for the treatment and prophylaxis of hepatitis b virus infection
EP4314011A4 (en) * 2021-03-24 2025-01-01 Anavex Life Sciences Corp. PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION
WO2022208262A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TWI869780B (zh) 2022-03-02 2025-01-11 美商輝瑞大藥廠 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統
WO2024149990A1 (en) 2023-01-10 2024-07-18 Oxford University Innovation Limited Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections
WO2024252327A1 (en) 2023-06-09 2024-12-12 Pfizer Inc. Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
WO2025037206A1 (en) 2023-08-11 2025-02-20 Pfizer Inc. Deuterated antiviral compounds
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025191272A1 (en) 2024-03-13 2025-09-18 Storm Therapeutics Ltd Inhibitory compounds
CN119707862B (zh) * 2025-02-24 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
JPH0780355B2 (ja) * 1987-01-22 1995-08-30 富士写真フイルム株式会社 光学的情報記録媒体
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
EP1680431A1 (en) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
CN101925300A (zh) * 2007-11-21 2010-12-22 雅培制药有限公司 作为大麻素受体配体的新化合物和其用途
AU2011218830B2 (en) * 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012155352A1 (en) * 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
JP2014528412A (ja) * 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Similar Documents

Publication Publication Date Title
JP2017515901A5 (show.php)
JP2013518107A5 (show.php)
JP2013032389A5 (show.php)
PH12018550201A1 (en) Hepatitis b antiviral agents
JP2014521688A5 (show.php)
BR112015014457A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
JP2015024998A5 (show.php)
JP2017537066A5 (show.php)
JP2016515561A5 (show.php)
TR201906470T4 (tr) İmmünomodülatörler.
NZ729150A (en) Antiretroviral agents
JP2012144574A5 (show.php)
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
PH12013500015A1 (en) 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
EA200901241A1 (ru) Соединения для лечения гепатита с
JP2016540742A5 (show.php)
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
JOP20210249A1 (ar) مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
JP2016540749A5 (show.php)
WO2012174312A3 (en) Benzimidazole derivatives as antiviral agents
ECSP13012438A (es) Proceso para preparar compuestos antivirales
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
RU2017103656A (ru) Производные изоиндолинона, полезные в качестве противовирусных средств